Publication:

Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus

Loading...
Thumbnail Image

Date

2018

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Frontiers Media S.A.
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Mizui, Masayuki, and George C. Tsokos. 2018. “Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus.” Frontiers in Immunology 9 (1): 786. doi:10.3389/fimmu.2018.00786. http://dx.doi.org/10.3389/fimmu.2018.00786.

Abstract

Regulatory T cells (Tregs) are central in integration and maintenance of immune homeostasis. Since breakdown of self-tolerance is a major culprit in the pathogenesis of systemic lupus erythematosus (SLE), restoration of the immune tolerance through the manipulation of Tregs can be exploited to treat patients with SLE. New information has revealed that Tregs besides their role in suppressing the immune response are important in tissue protection and regeneration. Expansion of Tregs with low-dose IL-2 represents an approach to control the autoimmune response. Moreover, control of Treg metabolism can be exploited to restore or improve their function. Here, we summarize the function and diversity of Tregs and recent strategies to improve their function in patients with SLE.

Description

Research Data

Keywords

Review, systemic lupus erythematosus, regulatory T cells, tissue Treg, low-dose IL-2 treatment, immunometabolism

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories